Winning Stock Forecast Ligand Pharmaceuticals Inc. (LGND). Returns up to 48.60% in 3 Months
Winning Stock Forecast Ligand Pharmaceuticals Inc. (LGND)
Our Winning Stock Forecast Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a mid-cap Biotech and Pharma company. The company has many programs of collaboration, in numbers, with 95 different Biotech and Pharmaceuticals companies including Baxter, Novartis, Pfizer and Bristol-Myers Squibb. Thanks to these collaborations, the company could arrive in 2020 to 24 new lines the product. However, shares have decreased about 14.9% since the last Earning report published in the end of September 2018. To confirm this, in mid-September price was $254.79 while the Average Volume for LGND shares was $344,030. Moreover, LGND’s low point in its 52 week range is $126.50 per share, with $278.62 as the 52 week high point The reasons for this drop are several. As reported in the last Earnings & Revenues Q3, Research & development (R&D) expenses increased 14.6% to $5.5 million and General & Administrative expenses rose 37.1% year over year to $9.6 million. License fees, milestones and other revenues were $2.5 million compared with $3.8 million compared to the same period last year. Material sales decreased 9.1% to $7 million in the year-ago quarter due to the unfavorable timing of Captisol purchases for clinical and commercial use. In terms of financial health, Ligand Pharmaceuticals has posted rising EPS growth in each of the last three reports in spite of analyst expectation. Revenue growth has also risen during the same period.
Algorithmic traders utilize daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster.
To learn how you can become a subscriber today, click here.
Please note-for trading decisions use the most recent forecast.
The Company
Ligand Pharmaceuticals Incorporated (Ligand), incorporated on September 28, 1987, is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver-targeted pro-drug technologies and antibody discovery technologies to assist companies in their work towards obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. The Company is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.
S&P 500 Forecast
The Winning Forecast is also for the index S&P 500. In this moment, firms being part of it, are in the market called bear, it means that they lost more than 20% in a given period. Some leading companies’ part of S&P 500 that have been in this position in the last weeks: FAANG, Facebook, Amazon, Apple, Netflix, and Google. All were in bear markets. Moreover, in the same time this companies decrease around 50% from the 52-weeks: Nektar Therapeutics, General Electric Co., PG&E Corp., and NVidia Corp. Additionally, in terms of estimate revisions for companies in the S&P 500, analysts have reduced EPS estimates within average levels for Q4 2018 to date. The chart below confirms what is in the I Know First Forecast for S&P 500. Many S&P 500 firms lowered expectations for the last quarter 2018 by reviewing earning estimate. Is visually appreciable the main responsibility of this decrease for the sectors Energy and Financial.
